Total Payments
$47,942
2024 Payments
$1,952
Companies
42
Transactions
300
Medicare Patients
1,270
Medicare Billing
$93,296
Payment Breakdown by Category
Other$29,513 (61.6%)
Food & Beverage$6,652 (13.9%)
Travel$6,369 (13.3%)
Consulting$5,407 (11.3%)
Education$0.90 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,513 | 14 | 61.6% |
| Food and Beverage | $6,652 | 276 | 13.9% |
| Travel and Lodging | $6,369 | 5 | 13.3% |
| Consulting Fee | $5,407 | 4 | 11.3% |
| Education | $0.90 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $38,127 | 33 | $0 (2023) |
| ARGENX US, INC. | $4,000 | 11 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $1,144 | 37 | $0 (2024) |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $587.99 | 38 | $0 (2024) |
| ABBVIE INC. | $504.74 | 20 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $367.19 | 20 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $324.27 | 18 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $210.00 | 11 | $0 (2024) |
| UCB, Inc. | $202.61 | 7 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $196.19 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,952 | 79 | Alexion Pharmaceuticals, Inc. ($295.34) |
| 2023 | $7,853 | 107 | Biogen, Inc. ($5,361) |
| 2022 | $28,957 | 77 | Biogen, Inc. ($24,184) |
| 2021 | $7,511 | 29 | Biogen, Inc. ($7,133) |
| 2020 | $1,618 | 6 | Biogen, Inc. ($1,450) |
| 2019 | $50.40 | 2 | Alexion Pharmaceuticals, Inc. ($50.40) |
All Payment Transactions
300 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $20.01 | General |
| Category: Rare Disease | ||||||
| 12/17/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $27.24 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/04/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $32.32 | General |
| Category: Immunology | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/14/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Genetic Disease | ||||||
| 11/11/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug), RADICAVA ORS | Food and Beverage | In-kind items and services | $23.72 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 11/05/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $132.39 | General |
| Category: Rare Disease | ||||||
| 11/04/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $28.10 | General |
| Category: Neurology | ||||||
| 10/28/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $28.27 | General |
| Category: Neurology | ||||||
| 10/10/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: Rare Disease | ||||||
| 10/08/2024 | Ipsen Biopharmaceuticals, Inc | Dysport (Drug) | Food and Beverage | In-kind items and services | $21.34 | General |
| Category: Neurology | ||||||
| 09/23/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $25.38 | General |
| Category: Rare Disease | ||||||
| 09/12/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $27.88 | General |
| Category: Neurology | ||||||
| 09/11/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug), RADICAVA ORS | Food and Beverage | In-kind items and services | $24.76 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 09/04/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $23.95 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 09/03/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $20.98 | General |
| Category: Central Nervous System | ||||||
| 08/28/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $31.34 | General |
| Category: Neurology | ||||||
| 08/27/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 08/22/2024 | Octapharma USA, Inc. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $13.75 | General |
| Category: IMMUNOLOGY | ||||||
| 08/21/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug), RADICAVA ORS | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 08/16/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $18.79 | General |
| Category: Central Nervous System | ||||||
| 08/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $24.68 | General |
| Category: IMMUNOLOGY | ||||||
| 08/13/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug), RADICAVA ORS | Food and Beverage | In-kind items and services | $5.21 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 08/12/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $19.12 | General |
| Category: Rare Disease | ||||||
| 08/01/2024 | Ipsen Biopharmaceuticals, Inc | Dysport (Drug) | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 390 | 506 | $86,830 | $31,202 |
| 2022 | 10 | 399 | 480 | $82,995 | $30,740 |
| 2021 | 10 | 364 | 424 | $69,595 | $25,715 |
| 2020 | 6 | 117 | 135 | $16,129 | $5,639 |
Total Patients
1,270
Total Services
1,545
Medicare Billing
$93,296
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 47 | 63 | $15,435 | $6,555 | 42.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 30 | 30 | $11,040 | $4,010 | 36.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 37 | 43 | $7,396 | $3,104 | 42.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 44 | $6,690 | $2,544 | 38.0% |
| 64644 | Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | Facility | 2023 | 16 | 29 | $8,294 | $2,472 | 29.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 39 | 47 | $5,217 | $2,308 | 44.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 20 | $6,220 | $1,743 | 28.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $4,895 | $1,604 | 32.8% |
| 95908 | Nerve conduction, 3-4 studies | Facility | 2023 | 28 | 29 | $4,495 | $1,355 | 30.1% |
| 95909 | Nerve conduction, 5-6 studies | Facility | 2023 | 23 | 23 | $3,105 | $1,329 | 42.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 13 | 14 | $3,162 | $1,193 | 37.7% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2023 | 29 | 35 | $3,990 | $1,101 | 27.6% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Facility | 2023 | 37 | 59 | $2,537 | $772.84 | 30.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 11 | 26 | $1,846 | $628.11 | 34.0% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Facility | 2023 | 19 | 33 | $2,508 | $482.65 | 19.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 63 | 75 | $18,375 | $7,550 | 41.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 31 | 31 | $11,408 | $3,914 | 34.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 40 | 50 | $8,600 | $3,375 | 39.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 30 | 42 | $6,384 | $2,897 | 45.4% |
| 95908 | Nerve conduction, 3-4 studies | Facility | 2022 | 49 | 50 | $7,750 | $2,302 | 29.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 22 | 29 | $6,728 | $2,217 | 32.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 17 | 19 | $5,909 | $2,168 | 36.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 16 | $3,680 | $1,477 | 40.1% |
| 95909 | Nerve conduction, 5-6 studies | Facility | 2022 | 25 | 25 | $3,375 | $1,335 | 39.5% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Facility | 2022 | 58 | 88 | $3,784 | $1,196 | 31.6% |
About Dr. Benjamin Barnes, MD
Dr. Benjamin Barnes, MD is a Neuromuscular Medicine healthcare provider based in Augusta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2015. The National Provider Identifier (NPI) number assigned to this provider is 1760866545.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Barnes, MD has received a total of $47,942 in payments from pharmaceutical and medical device companies, with $1,952 received in 2024. These payments were reported across 300 transactions from 42 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($29,513).
As a Medicare-enrolled provider, Barnes has provided services to 1,270 Medicare beneficiaries, totaling 1,545 services with total Medicare billing of $93,296. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Neuromuscular Medicine
- Other Specialties Neurology, Neuromusculoskeletal Medicine & OMM
- Location Augusta, GA
- Active Since 07/12/2015
- Last Updated 09/07/2022
- Taxonomy Code 2084N0008X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1760866545
Products in Payments
- SPINRAZA (Biological) $30,179
- Spinraza (Biological) $5,361
- ULTOMIRIS (Biological) $802.76
- RADICAVA (Drug) $587.09
- BOTOX (Biological) $321.86
- VYVGART (Drug) $264.90
- Austedo XR (Drug) $206.93
- INGREZZA (Drug) $204.64
- QULIPTA (Drug) $178.37
- RELYVRIO (Drug) $174.11
- VYVGART HYTRULO (Drug) $172.10
- Xeomin (Biological) $171.97
- NURTEC ODT (Drug) $161.07
- Dysport (Drug) $149.59
- AMVUTTRA (Drug) $138.82
- AUSTEDO (Drug) $126.63
- Evrysdi (Drug) $121.63
- SOLIRIS (Biological) $119.82
- Ongentys (Drug) $119.63
- Hizentra (Biological) $115.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.